Results 161 to 170 of about 601,324 (309)

Deregulation, Consolidation, and Efficiency: Evidence From the Spanish Insurance Industry [PDF]

open access: yes
This paper provides new information on the effects of deregulation and consolidation in financial services markets by analyzing the Spanish insurance industry.
J. David Cummins, Maria Rubio-Misas
core  

Drivers of Nature‐Related Investment Strategies Among Institutional Investors

open access: yesBusiness Strategy and the Environment, EarlyView.
ABSTRACT Institutional investors are increasingly responding to biodiversity loss through nature‐related investment strategies. Using survey data from 557 institutional investors, this study examines the drivers of strategy selection and how biodiversity risk is integrated across investor types, sizes, and regions.
Emma Olofsson
wiley   +1 more source

Takeover Vulnerability and the Discipline of ESG Overinvestment

open access: yesBusiness Strategy and the Environment, EarlyView.
ABSTRACT While takeovers serve a disciplinary role by replacing inefficient managers, the threat of takeovers may compel firms to divert attention from Environmental, Social and Governance (ESG) efforts as a strategic response to external pressure, especially when such firms are already overinvesting in ESG.
Abongeh Tunyi   +2 more
wiley   +1 more source

Supercritical water deasphalting and desulphurization of heavy fuel oil with comprehensive molecular‐level analysis and techno‐economic analysis

open access: yesThe Canadian Journal of Chemical Engineering, EarlyView.
Supercritical water deasphalting. Abstract The removal of sulphur from heavy fuel oil (HFO) is essential to address environmental concerns and comply with the stringent regulations imposed by the International Maritime Organization (IMO) in 2020. Previously, the acceptable limit for sulphur was 3.5 wt.%, but it was recently changed to 0.5 wt.%.
Biswajit Saha   +6 more
wiley   +1 more source

Measuring the Impact of the Substitution of Innovator Biologics With Biosimilars on Uptake and Costs Among Ontario Public Drug Benefit Recipients

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
In Ontario, biologics have historically represented a small proportion of public drug claims but a large proportion of spending. Biosimilars, lower cost alternatives to biologics, offer a potential solution to the rising spending on biologics. From March 2023 to January 2024, the Ontario Ministry of Health required public drug program beneficiaries on ...
Anita Iacono   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy